{"entity":{"id":"nct07011186","kind":"trial","name":"A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies","aka":[],"tldr":"A phase 1/2 trial of Azacitidine in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.","summary":"A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies is a phase 1/2 interventional study registered as NCT07011186 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 138 participants planned, started 2024-04-17 and due to reach its primary completion in 2025-10. Interventions recorded: TQB3909 Tablets + Azacitidine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07011186","url":"https://clinicaltrials.gov/study/NCT07011186"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["azacitidine"],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07011186","phase":"1/2","setting":"A Phase Ib/II Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of TQB3909 Tablets in Combination With Azacitidine in Subjects With Myeloid Malignancies","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","enrolled":138,"outcomes":[]},"route":"/trials/nct07011186/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"},{"id":"tqb3909","kind":"drug","name":"TQB3909","route":"/drugs/tqb3909/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}]}}